Entries by erik abrahamsson

Bio-Works launches WorkBeads affimAb for purification of tomorrow’s biological pharmaceuticals

Press release October 9, 2018 Bio-Works today announces the launch of WorkBeads affimAb for purification of new biological pharmaceuticals on a large scale. As for all Bio-Works’ products, focus is on improved production efficiency. We aim to capture the target molecule (the pharmaceutical product) in the shortest possible time and to achieve a purification process […]

Bio-Works forms distinguished Scientific Advisory Board

Press release September 10, 2018 Bio-Works has recruited four distinguished scientists with industrial experience to its Scientific Advisory Board (SAB). The purpose of the SAB is to bring in qualified advisors for strategic and tactical issues regarding Bio-Works’ technical, product and marketing focus. During the spring and summer, Bio-Works has recruited the following advisors to […]

Bio-Works separation media, WorkBeads™, is being used for full scale production of an FDA approved biopharmaceutical

Press release April 12, 2018 Bio-Works’ separation media, WorkBeads, has become standard for the production of an FDA approved biopharmaceutical which is being used globally for treatment of patients. This pharmaceutical is the first of several ongoing pharmaceutical projects, where WorkBeads is being used, which has come all the way from lab scale to full […]

Bio-Works opens sales office in USA

Press release March 20th 2018 Bio-Works has opened a sales office in Philadelpia, USA to meet the large demand for separation and purification products for the production of biological medicine in the American market. To be able to support the customers at the right competence level the office will initially be manned with Swedish personnel. […]

Bio-Works secures another order from PolyPeptide

Press release Februari 23 2018 Bio-Works has received an order of 1,0 million SEK from PolyPeptide. During 2017 Bio-Works received four orders from PolyPeptide, which is one of the largest contract manufacturers in the world for peptide pharmaceuticals. They have 25 % of the global market for contract manufacturing of peptide pharmaceuticals. This order will […]

Bio-Works säkrar ytterligare en order från PolyPeptide

Pressmeddelande den 23 februari 2018, kl: 07:37 Bio-Works har erhållit en order värd 1,0 miljon kronor från PolyPeptide. Under 2017 erhöll Bio-Works fyra ordrar från PolyPeptide, som är en av världens största kontraktstillverkare av peptidläkemedel och står för 25 % av den globala produktionen av peptidläkemedel hos kontraktstillverkare. Den senaste ordern kommer att levereras till […]

Interview with Dr. Yong Chul Shin, CEO of Amicogen Inc.

Amicogen Inc. is the largest shareholder in Bio-Works Technologies AB as of today, with slighty less than 10% of the shares. The planned listing on First North Stockholm is set to 14th of december. 1. What do you think makes Bio-Works unique? “Bio-Works has developed a protein purification resin optimized for its customers through its long […]